PUBLISHER: The Business Research Company | PRODUCT CODE: 2035919
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035919
Edge bioinformatics for sequencing involves analyzing genomic sequencing data at or near the location where it is generated, using local computing resources such as onboard processors, portable devices, or on-site servers instead of centralized or cloud-based systems. This method allows real-time or near real-time processing of sequencing data, reducing data transfer needs, latency, and reliance on high-bandwidth connectivity.
The key sequencing technologies of edge bioinformatics for sequencing include next-generation sequencing, Sanger sequencing, third-generation sequencing, and others. Next-generation sequencing (NGS) is a high-throughput technology that rapidly determines the precise order of nucleotides in DNA or RNA molecules. Components include hardware, software, and services, with deployment modes such as on-device edge deployment, on-premises edge deployment, and hybrid edge and cloud deployment. Applications include clinical diagnostics, field research, forensics, drug discovery, and public health and disease surveillance, serving hospitals and clinics, biotechnology and pharmaceutical companies, academic and research institutes, and government and public health organizations.
Tariffs on imported sequencing hardware, bioinformatics processors, and networking components are impacting the edge bioinformatics for sequencing market by increasing costs for hardware and software providers, particularly affecting on-device and on-premises edge deployment segments. Regions such as North America, Europe, and Asia-Pacific that rely on imported sequencing instruments and computing modules are most affected. While tariffs raise procurement costs, they also encourage local manufacturing, stimulate domestic innovation in portable sequencing devices, and foster the development of cost-efficient edge bioinformatics solutions.
The edge bioinformatics for sequencing market research report is one of a series of new reports from The Business Research Company that provides edge bioinformatics for sequencing market statistics, including edge bioinformatics for sequencing industry global market size, regional shares, competitors with a edge bioinformatics for sequencing market share, detailed edge bioinformatics for sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the edge bioinformatics for sequencing industry. This edge bioinformatics for sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The edge bioinformatics for sequencing market size has grown rapidly in recent years. It will grow from $1.99 billion in 2025 to $2.31 billion in 2026 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to increasing adoption of next generation sequencing technologies, growth in genomics research, rising demand for rapid diagnostic tools, expansion of biotechnology infrastructure, development of portable sequencing devices.
The edge bioinformatics for sequencing market size is expected to see rapid growth in the next few years. It will grow to $4.21 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to growing adoption of AI-driven sequencing analysis, increasing deployment of on-device edge computing, rising demand for real-time field diagnostics, expansion of public health surveillance programs, integration of hybrid edge-cloud sequencing platforms. Major trends in the forecast period include increasing adoption of on-device edge sequencing, rising integration of real-time data analytics in sequencing, expansion of portable and field-deployable sequencing platforms, growing focus on clinical diagnostics and personalized medicine, rising demand for hybrid edge and cloud sequencing solutions.
The rise of precision medicine is anticipated to drive the growth of the edge bioinformatics for sequencing market in the coming years. Precision medicine is a tailored healthcare approach that leverages genetic, environmental, and lifestyle information to provide targeted and more effective treatments for individual patients. Its adoption is accelerating due to advancements in genomic sequencing technologies, which have made sequencing faster, more accurate, and more cost-effective, allowing treatment decisions to be customized to an individual's genetic profile. As precision medicine increasingly relies on large-scale genomic data and rapid analysis, centralized cloud-based bioinformatics face challenges such as latency, bandwidth requirements, and data privacy issues. Edge bioinformatics for sequencing addresses these challenges by enabling real-time, on-site genomic data analysis, facilitating quicker mutation detection and more timely personalized clinical decisions. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023 the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growth of precision medicine is propelling the expansion of the edge bioinformatics for sequencing market.
The increase in healthcare expenditure is expected to contribute to the growth of the edge bioinformatics for sequencing market in the coming years. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, and governments on the prevention, diagnosis, treatment, and management of health conditions. This spending is rising primarily due to advancements in medical technology, as the adoption of sophisticated diagnostic tools, genomic sequencing platforms, and innovative therapies often entails higher costs and sustained investment. Growing healthcare expenditure allows healthcare systems, research institutions, and life sciences companies to allocate more resources toward advanced genomic infrastructure, including high-throughput sequencing technologies and real-time data analysis capabilities. For instance, in December 2024, the Centers for Medicare & Medicaid Services (CMS), a US-based agency responsible for administering Medicare and Medicaid programs, reported that U.S. healthcare expenditures increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, rising healthcare expenditure is driving the growth of the edge bioinformatics for sequencing market.
The rising research and development investments are expected to propel the growth of the edge bioinformatics for sequencing market moving forward. Research and development (R&D) investments refer to the allocation of resources toward creating new products, enhancing existing offerings, and advancing technologies to drive innovation and long-term business growth. Growing technological advancements are fueling increased research and development investments, as companies need to continuously innovate and upgrade their products and processes to keep pace with rapid digital transformation and evolving industry standards. Research and development (R&D) investments support edge bioinformatics for sequencing by enabling the creation of advanced algorithms, optimized hardware integration, and real-time data processing capabilities that allow genomic data to be analyzed directly at or near sequencing devices, reducing latency, cutting data transfer costs, and accelerating clinical and research decision-making. For example, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government's net spending on research and development (R&D) rose to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% increase. Therefore, rising research and development investments are driving the growth of the edge bioinformatics for sequencing market.
Major companies operating in the edge bioinformatics for sequencing market are Roche Holding AG, Thermo Fisher Scientific Inc., BC Platforms Ltd., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc, Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., Azenta Life Sciences Inc., BGI Genomics Co. Ltd., Novogene Co. Ltd., Seven Bridges Genomics Inc., Genedata AG, DNAnexus Inc., Oxford Nanopore Technologies Ltd., Saphetor SA, Strand Life Sciences Pvt. Ltd., PierianDx Inc., DNASTAR Inc., Golden Helix Inc., Partek Incorporated.
North America was the largest region in the edge bioinformatics for sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the edge bioinformatics for sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the edge bioinformatics for sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The edge bioinformatics for sequencing market consists of revenues earned by entities by providing services such as real-time basecalling and signal processing, on-device read alignment and genome mapping, and quality control and run performance monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The edge bioinformatics for sequencing market also includes sales of compact edge AI accelerators, portable laptops, and mobile DNA sequencing SoC prototypes. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Edge Bioinformatics For Sequencing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses edge bioinformatics for sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for edge bioinformatics for sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The edge bioinformatics for sequencing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.